Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® HCV / Hepatitis specialty page provides HCV / hepatitis-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


Safety of New HCV Direct-Acting Antivirals Called into Question
A report warns that liver failure might be associated with nine new direct-acting antivirals (DAA).
Too Many Conflicts of Interest Found in HCV Management Guidelines
A group of researchers recently published a study in JAMA, examining conflicts of interest (COIs) among committee members who set hepatitis C (HCV) and cholesterol management guidelines. They found that there, in fact, were COIs among committee members setting HCV management guidelines.
Gilead's Combination Therapy for HCV Has Been Validated by The EMA
The European Medicines Agency has fully validated Gilead’s SOf/VEL/VOX regimen to treat hepatitis C (HCV).
Is Interferon Therapy Behind Cognitive Decline in HCV Patients?
Felix Kleefeld, of Berlin, Germany, and colleagues examined how eradicating HCV affected the cognition of patients in a study published in Neurology in December 2016.
HCV Treatment Achieves Viral Suppression in Less Than 12 Weeks
Researchers conducted a post hoc analysis to learn whether or not the length of time it took to attain initial viral suppression is related to sustained virologic response (SVR) rates for patients receiving the so-call 3D treatment, with or without ribavirin.
Class-Action Lawsuit Filed Against Insurance Company Over Denied Harvoni Coverage Dropped
Insurance companies are denying members coverage to expensive drugs, like Harvoni, and those infected with HCV are filing lawsuits.
New Project Dedicated to Developing New Strategies to Fight Hepatitis C
A new project aims to develop and assess new hepatitis C vaccination strategies in an effort to improve treatment.
Researchers Find New Therapeutic Target Against Chronic Viral Infections
Researchers offer more insight on the role of IFN-I and find a potential therapeutic target that may be able to protect against chronic viral infections.
Big advances in treatment can